查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012946

牛呼吸道疾病治疗药物市场：按产品类型、给药途径、目标动物和分销管道分類的全球市场预测，2026-2032年

Bovine Respiratory Disease Treatment Market by Product Type, Route Of Administration, Animal Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，牛呼吸道疾病治疗市场价值将达到 22.3 亿美元，到 2026 年将成长至 23.7 亿美元，到 2032 年将达到 38.4 亿美元，复合年增长率为 8.05%。

主要市场统计数据
基准年 2025 22.3亿美元
预计年份：2026年 23.7亿美元
预测年份 2032 38.4亿美元
复合年增长率 (%) 8.05%

治疗牛呼吸系统疾病的策略方法：使治疗方法方案与临床实际情况、监管趋势和营运重点保持一致。

牛呼吸道疾病仍然是全球畜牧业面临的最持久、最具经济影响的健康挑战之一。本文将读者置于临床实务、药物研发和供应链演变的交会点，揭示临床因素、监管压力和生产经济如何相互作用，共同塑造治疗策略。此疾病群包含病毒和细菌病原体，通常需要综合治疗和预防措施。此外，抗生素和疫苗的相互作用在任何有效的控制方案中都起着至关重要的作用。

科学创新、管理方法的进步以及分销系统的重组如何重塑治疗策略和临床实践的范式？

牛呼吸道疾病的治疗格局正在经历一场变革，这主要得益于科学创新、监管改革和生产方式的转变。疫苗技术和製剂科学的进步，透过开发专门针对主要病毒和细菌病原体的灭活疫苗和减毒活病毒疫苗平台，正在拓展预防选择。同时，抗生素分类和给药策略的改进，正推动在不影响临床患病动物治疗效果的前提下，合理使用抗菌药物的目标不断实现。

近期关税政策更新对供应链、采购惯例以及牛健康管理中基本治疗药物的持续获取的实际影响。

美国2025年前的关税政策发展正在影响整个动物保健生态系统的供应链决策、筹资策略和成本结构。进口关税和海关程序的变化正在影响成品药、疫苗成分和活性成分的分销，迫使製造商和经销商重新评估筹资策略和库存布局，以维持供应的连续性。拥有复杂全球供应链的公司被迫考虑近岸外包、双重采购和策略储备等措施，以减轻关税带来的衝击。

从治疗领域、给药途径、目标动物特征和通路与临床和商业策略之间进行详细的细分观点。

细分市场分析揭示了每种产品类别、给药途径、动物种类和通路的不同机会和临床考虑。在产品类型方面，抗生素包括不同的药理学家族，例如β-内酰胺类、Fluoroquinolones、大环内酯类和四环霉素，其中大环内酯类又包括胸苷霉素、曲曲霉素和泰乐菌素等药物。疫苗属于预防领域，分为灭活疫苗和减毒活疫苗。灭活疫苗针对牛呼吸道融合细胞病毒（BRSV）、巴氏桿菌和副流感病毒3型（PI3）等病原体；减毒活病毒疫苗也针对BRSV、曼氏桿菌和PI3。每种疫苗的免疫抗原性特征和对低温运输的影响各不相同。

区域生产系统、法规环境和分销基础设施如何塑造差异化的治疗方法和实施策略。

区域趋势影响着美洲、欧洲、中东和非洲以及亚太地区的临床重点、监管预期和分销策略。在美洲，生产系统涵盖大规模商业育肥场到家庭式酪农，由此产生了多样化的治疗需求，因此管理计划和可追溯性备受重视。疫苗宣传活动和针对性抗生素计划透过兽医网络和一体化供应链进行协调，饲料厂和兽医诊所在产品分销中发挥着至关重要的作用。

为了因应临床需求和供应链挑战，各公司正专注于策略应对措施，重点在于配方创新、通路伙伴关係和诊断整合。

主要企业洞察凸显了行业相关人员如何应对临床需求、日益复杂的供应链以及不断演变的分销模式。领先的研发和供应公司正投资于製剂创新，以优化稳定性、减少对低温运输的依赖，并拓展口服和鼻腔给药途径，从而实现大剂量给药。其他公司则在继续支持符合药品管理指南和标籤优化的同时，改进其註射剂产品组合，以增强药物动力学特性并提高给药便利性。

为製造商和经销商提供实际有效的措施，以加强管理、供应链韧性以及农场治疗药物和疫苗的供应。

针对行业领导者的实际建议着重于使产品系列与管理目标保持一致、增强供应链韧性以及改善终端用户的获取途径。优先考虑平衡治疗方案和预防平台的产品组合策略，投资于能够降低疾病发生率的疫苗技术和支持符合管理原则的抗生素製剂。同时，应扩大给药途径的开发，例如鼻腔给药和饲料/饮水中的口服给药，以减轻操作负担并促进群体层面的干预措施。

透过严谨且多方面的研究途径，结合对第一线临床医生的访谈、供应链分析和文献整合，获得了切实可行的临床和商业性见解。

本报告的调查方法透过整合多方面证据、专家访谈和情境分析，确保了其可靠性和可操作性。为了了解实际操作和采购行为，我们对临床医生、动物健康专家、饲料厂经理和分销主管进行结构化访谈，并将访谈作为主要资讯来源。这些定性研究结果与疫苗平台、抗生素分类和给药科学的专家文献进行了交叉比对，以确保临床准确性并阐明其对营运的影响。

一份简洁、全面的分析报告强调，综合预防、以管理主导的治疗和供应链适应性是永续疾病管理的基础。

总之，有效管理牛呼吸道疾病需要综合策略，该策略应结合治疗方法创新、实用给药方法和完善的配送体系。疫苗技术和药物科学的进步提供了有效的预防措施，而精细的抗生素策略和合理的用药规范则能维持临床病例的治疗效果。给药途径的选择必须考虑农场的实际情况、不同动物（如牛、牛和牛）的具体情况以及现有通路的限制。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：牛隻呼吸系统疾病治疗市场：依产品类型划分

  • 抗生素
    • β-内酰胺
    • Fluoroquinolones
    • 大环内酯类
      • 奇尔米考辛
      • 曲菌
      • 泰乐菌素
    • 四环霉素
  • 疫苗
    • 失活
      • BRSV
      • 巴斯德氏菌
      • PI3
    • 活病毒疫苗
      • BRSV
      • 曼海姆
      • PI3

第九章：牛呼吸系统疾病治疗药物市场：依给药途径划分

  • 注射药物
    • 肌肉内部
    • 静脉
    • 皮下
  • 鼻内
  • 口服
    • 饲料
    • 水

第十章：牛呼吸系统疾病治疗市场：依动物类型划分

  • 牛
    • 牛
    • 牛
  • 牛
    • 牛牛犊
    • 乳牛
  • 小母牛

第十一章：牛隻呼吸系统疾病治疗市场：依分销管道划分

  • 饲料厂
    • 商业麵粉厂
    • 农场自有麵粉厂
  • 网路药房
    • 动物用药品平台
    • 一般电子商务零售
  • 动物医院
    • 独立动物医院
    • 大型诊所

第十二章：牛隻呼吸系统疾病治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：牛隻呼吸系统疾病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：牛隻呼吸系统疾病治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国牛呼吸系统疾病治疗市场

第十六章：中国牛隻呼吸系统疾病治疗药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aratana Therapeutics, Inc.
  • Ashish Life Science Pvt. Ltd.
  • Bimeda Inc.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Huvepharma AD
  • IDEXX Laboratories, Inc.
  • India Immunologicals Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Intas Pharmaceuticals Ltd.
  • Kyoritsu Seiyaku Corporation
  • Med-Pharmex Ltd.
  • Merck & Co., Inc.
  • Neogen Corporation
  • Novartis Animal Health
  • Ourofino Saude Animal SA
  • Phibro Animal Health Corporation
  • Plumbline Life Sciences
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
  • Zydus Animal Health and Investments Limited
Product Code: MRR-437D4595869F

The Bovine Respiratory Disease Treatment Market was valued at USD 2.23 billion in 2025 and is projected to grow to USD 2.37 billion in 2026, with a CAGR of 8.05%, reaching USD 3.84 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.23 billion
Estimated Year [2026] USD 2.37 billion
Forecast Year [2032] USD 3.84 billion
CAGR (%) 8.05%

A strategic orientation to bovine respiratory disease treatment that aligns therapeutic choices with clinical realities, regulatory dynamics, and operational priorities

Bovine respiratory disease remains one of the most persistent and economically significant health challenges in cattle production systems globally. This introduction situates the reader at the intersection of clinical practice, pharmaceutical development, and supply chain evolution, highlighting how clinical drivers, regulatory pressures, and production economics collectively shape treatment strategies. The disease complex itself encompasses viral and bacterial etiologies that frequently require integrated therapeutic and preventive responses, and the interplay between antibiotics and vaccines is central to any effective control program.

Clinicians and herd managers increasingly rely on evidence-based protocols that balance animal welfare, antimicrobial stewardship, and operational efficiency. In this context, treatment selection is influenced by pathogen prevalence, animal category, route of administration suitability, and distribution channel accessibility. The landscape has been further complicated by shifting regulations and growing emphasis on reduced antimicrobial use, which amplifies the role of targeted vaccination programs and alternative delivery modalities.

This introduction therefore frames the subsequent analysis around four core dimensions: therapeutic modalities and formulations, administration routes and on-farm logistics, animal demographic considerations, and distribution ecosystems. By grounding the discussion in these pillars, readers will gain a practical orientation that supports strategic decisions in product development, clinical implementation, and commercial planning.

How scientific innovation, evolving administration methods, and distribution reconfiguration are reshaping treatment strategies and clinical practice paradigms

The treatment landscape for bovine respiratory disease is undergoing transformative shifts driven by scientific innovation, regulatory recalibration, and changing production practices. Advances in vaccine technology and formulation science are enabling broader preventive options, with inactivated and live attenuated platforms tailored to protect against core viral and bacterial agents. At the same time, refinement of antibiotic classes and dosing strategies is advancing antimicrobial stewardship objectives without sacrificing therapeutic potency for clinically ill animals.

Equally consequential are shifts in administration practices. Injectable delivery remains central to rapid systemic therapy, but intranasal vaccines and oral delivery via feed or water are gaining practical traction because they simplify mass administration and reduce handling stress. These changes intersect with animal demographics: protocols differ substantively between adult cattle populations, which include distinct beef and dairy management considerations, and younger cohorts such as beef calves and dairy calves where immune maturity and management systems affect both prevention and treatment timing.

Distribution systems are evolving in parallel. Traditional veterinary clinic channels continue to deliver clinical oversight and prescription-based treatments, yet feed mills-both commercial and onfarm-and online animal health platforms are reshaping access and procurement behaviors. Together, these trends are reconfiguring go-to-market strategies for product developers and suppliers, prompting new partnerships across pharmaceutical, feed, and veterinary service providers.

The practical ramifications of recent tariff policy updates on supply chains, procurement practices, and continuity of access for essential therapies in cattle health

Tariff policy developments in the United States for 2025 have influenced supply chain decisions, procurement tactics, and cost structures across the animal health ecosystem. Changes to import duties and customs protocols affect the flow of finished pharmaceuticals, vaccine components, and active ingredients, prompting manufacturers and distributors to reassess sourcing strategies and inventory positioning to preserve continuity of supply. Firms with complex global supply chains have been compelled to evaluate nearshoring, dual-sourcing, and strategic stockpiling as mitigants against tariff-driven disruptions.

These shifts have downstream effects on stakeholders from feed mill operators to veterinary clinics. Feed mills sourcing medicated premixes and onfarm mills procuring therapeutics now face altered landed costs that can impact the pricing and availability of oral medications administered via feed or water. Similarly, online animal health platforms and general eRetailers importing niche formulations may adjust catalog offerings to manage margin pressures or compliance complexity. For animal producers, the practical implication is increased attention to procurement timelines and supplier reliability, as well as a renewed focus on preventive measures such as vaccination campaigns that reduce reliance on imported therapeutic products.

Regulatory harmonization and trade facilitation efforts remain important variables. Where tariff changes create friction, collaborative industry responses-such as pooled procurement, supplier diversification, and local formulation development-are emerging as pragmatic adaptations. These responses prioritize uninterrupted access to essential therapies and vaccines while maintaining adherence to clinical protocols and stewardship commitments.

An in-depth segmentation perspective linking therapeutic categories, administration routes, animal demographics, and distribution pathways to clinical and commercial strategies

Segmentation insights reveal differentiated opportunities and clinical considerations across product classes, administration routes, animal types, and distribution pathways. Within product type, antibiotics encompass distinct pharmacological families including beta lactams, fluoroquinolones, macrolides, and tetracyclines, with macrolides further represented by agents such as tilmicosin, tulathromycin, and tylosin. Vaccines occupy preventive space and are stratified into inactivated platforms targeting pathogens like bovine respiratory syncytial virus, Pasteurella and parainfluenza 3, and live attenuated formulations that also target BRSV, Mannheimia, and PI3, each with different immunogenic profiles and cold-chain implications.

Route of administration is a pivotal segmentation lens: injectable therapies are administered intramuscularly, intravenously or subcutaneously and remain the standard when systemic concentrations and rapid onset are required. Intranasal delivery offers localized immune priming especially valuable in young stock, while oral routes administered through feed or water enable mass medication strategies that reduce handling but require careful dosing control and palatability considerations. Animal type further differentiates clinical protocols; adult cattle populations, encompassing both beef and dairy cattle, have distinct production objectives and stewardship constraints compared with calves and heifers where immune competence and management system vulnerability influence timing and regimen selection. Calves in beef and dairy systems may necessitate earlier preventive interventions and tailored therapeutic approaches.

Distribution channel segmentation highlights the service and logistics dimension. Feed mills-both commercial and onfarm-play a role in delivering medicated feeds and supporting oral administration strategies. Online pharmacies operate as animal health platforms and generalized eRetail channels, broadening access to products where regulatory frameworks permit. Veterinary clinics, from independent practices to large multi-site groups, continue to provide clinical oversight, diagnostics, and prescription-based therapies. Understanding these intersecting segments enables stakeholders to align product development, packaging, cold-chain design, and commercial models with end-user requirements and operational realities.

How regional production systems, regulatory environments, and distribution infrastructures are shaping differentiated treatment approaches and deployment strategies

Regional dynamics shape clinical priorities, regulatory expectations, and distribution strategies across the Americas, Europe, Middle East & Africa, and the Asia-Pacific. In the Americas, production systems span large-scale commercial feedlots to family-run dairy operations, yielding diverse treatment needs and a strong emphasis on stewardship programs and traceability. Vaccination campaigns and targeted antibiotic regimens are coordinated through veterinary networks and integrated supply chains, with feed mills and veterinary clinics playing prominent roles in product distribution.

Within Europe, Middle East & Africa, regulatory frameworks and stewardship initiatives often drive conservative antibiotic use and increased adoption of preventive strategies. This region demonstrates variable infrastructure capacity, from highly developed cold-chain systems in parts of Europe to more fragmented distribution networks in some Middle Eastern and African markets, which influences the practical adoption of live attenuated vaccines and injectable formulations. The Asia-Pacific region is characterized by rapid growth in intensive production systems, diverse regulatory environments, and an expanding role for online animal health platforms and commercial feed mills. In many Asia-Pacific markets, the scale of production and proximity to manufacturing hubs create unique logistics advantages and challenges, particularly around feed- and water-administered therapies.

Across regions, the practical implications for stakeholders include alignment of product formats with logistical realities, sensitivity to regulatory and stewardship frameworks, and tailoring of commercial approaches to local procurement behaviors. Cross-regional knowledge transfer and adaptive implementation strategies are therefore essential for successful deployment of therapeutics and preventive programs.

Strategic corporate responses highlighting formulation innovation, channel partnerships, and diagnostic integration to meet clinical needs and supply chain challenges

Key company insights emphasize how industry participants are responding to clinical demands, supply chain complexity, and shifting distribution models. Leading developers and suppliers are investing in formulation innovation to optimize stability, reduce cold-chain dependency, and expand oral and intranasal options that facilitate mass administration. Others are refining injectable portfolios to improve pharmacokinetic profiles and dosing convenience, while continuing to support stewardship-aligned guidance and label optimization.

Strategic partnerships are increasingly important; collaborations between pharmaceutical firms, feed producers, and veterinary service providers enable integrated solutions that align therapeutic products with onfarm delivery capabilities. Companies with diversified distribution networks, including relationships with commercial and onfarm feed mill operators, online animal health platforms, and both independent and large veterinary practices, are better positioned to manage channel-specific demands and regulatory nuances. Additionally, manufacturers addressing tariff and supply continuity challenges are exploring regional manufacturing and contract manufacturing arrangements to shorten supply lines and enhance responsiveness.

innovation in diagnostics and data-driven health management is another focal area, as companies that integrate diagnostic support with product offerings help clinicians implement targeted therapies and measure intervention outcomes. The commercial implication is that companies combining therapeutic breadth, distribution agility, and diagnostic enablement can differentiate by delivering both clinical value and operational efficiencies to producers and veterinarians.

Practical, high-impact steps for manufacturers and distributors to strengthen stewardship, supply chain resilience, and on-farm accessibility of treatments and vaccines

Actionable recommendations for industry leaders focus on aligning product portfolios with stewardship goals, strengthening supply chain resilience, and enhancing end-user accessibility. Prioritize portfolio strategies that balance therapeutic options and preventive platforms, investing in vaccine technologies that reduce disease incidence and in formulations that support stewardship-compliant antibiotic use. Simultaneously, expand development into administration modalities such as intranasal and oral feed or water delivery to lower handling burdens and facilitate herd-level interventions.

Operationally, pursue supply chain diversification and nearshoring where feasible to mitigate tariff exposure and ensure uninterrupted access to critical raw materials and finished products. Strengthen partnerships with feed mills, online animal health platforms, and veterinary networks to create integrated procurement pathways that reflect how producers obtain therapeutics and vaccines in practice. Invest in cold-chain optimization where live attenuated vaccines demand stricter temperature control, while exploring formulation stability enhancements that reduce dependency on complex logistics.

Commercially, develop education and stewardship programs aimed at veterinarians and producers that emphasize diagnostic-led treatment, appropriate route selection, and age- and production-specific protocols for adult cattle, calves, and heifers. Leverage diagnostic tools and data analytics to demonstrate intervention outcomes, and design pricing and access models that support both smallholder and large-scale operations to maximize adoption and clinical impact.

A rigorous, multi-source research approach combining frontline clinician interviews, supply chain mapping, and literature synthesis to produce actionable clinical and commercial insights

The research methodology underpinning this report integrates multi-source evidence synthesis, expert consultation, and scenario-based analysis to ensure robustness and practical relevance. Primary inputs included structured interviews with clinicians, herd health specialists, feed mill managers, and distribution executives to capture frontline practices and procurement behaviors. These qualitative insights were triangulated with technical literature on vaccine platforms, antibiotic classes, and administration science to ensure clinical accuracy and to contextualize operational implications.

Secondary sources comprised peer-reviewed journals, regulatory guidance documents, and publicly available industry reports that elucidate therapeutic mechanisms, stewardship frameworks, and logistics considerations. The methodology also applied supply chain mapping to understand sourcing pathways for active pharmaceutical ingredients, formulation components, and finished goods, allowing identification of potential chokepoints and adaptive strategies in response to tariff changes. Analytical frameworks emphasized translational relevance, focusing on actionable insights for product development, distribution strategy, and clinical implementation rather than quantitative market projections.

Throughout the research process, findings were validated by cross-checking clinician perspectives against veterinary practice guidelines and by obtaining feedback from distribution channel stakeholders to ensure that recommendations reflect real-world constraints and opportunities.

A concise synthesis emphasizing integrated prevention, stewardship-led therapeutics, and supply chain adaptability as the foundation for durable disease control

In conclusion, effective management of bovine respiratory disease requires integrated strategies that bridge therapeutic innovation, administration practicality, and resilient distribution models. Advancements in vaccine technology and formulation science provide meaningful preventive options, while refined antibiotic strategies and stewardship practices preserve therapeutic effectiveness for clinical cases. The choice of administration route must reflect operational realities on farm, individual animal factors such as adult cattle, calves, and heifers, and the constraints of available distribution channels.

Supply chain dynamics, including the implications of tariff adjustments, underscore the importance of diversification and regional adaptability. Companies that align product design with logistical capabilities-such as injectable formats, intranasal options, and oral feed- and water-administered therapies-will be better positioned to support veterinarians and producers across varied regional contexts. Finally, collaboration across pharmaceutical developers, feed suppliers, diagnostic providers, and veterinary networks is essential to deliver clinically sound, operationally feasible, and stewardship-aligned solutions that improve herd health outcomes and sustain long-term therapeutic efficacy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bovine Respiratory Disease Treatment Market, by Product Type

  • 8.1. Antibiotics
    • 8.1.1. Beta Lactams
    • 8.1.2. Fluoroquinolones
    • 8.1.3. Macrolides
      • 8.1.3.1. Tilmicosin
      • 8.1.3.2. Tulathromycin
      • 8.1.3.3. Tylosin
    • 8.1.4. Tetracyclines
  • 8.2. Vaccines
    • 8.2.1. Inactivated
      • 8.2.1.1. BRSV
      • 8.2.1.2. Pasteurella
      • 8.2.1.3. PI3
    • 8.2.2. Live Attenuated
      • 8.2.2.1. BRSV
      • 8.2.2.2. Mannheimia
      • 8.2.2.3. PI3

9. Bovine Respiratory Disease Treatment Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
  • 9.2. Intranasal
  • 9.3. Oral
    • 9.3.1. Feed
    • 9.3.2. Water

10. Bovine Respiratory Disease Treatment Market, by Animal Type

  • 10.1. Adult Cattle
    • 10.1.1. Beef Cattle
    • 10.1.2. Dairy Cows
  • 10.2. Calves
    • 10.2.1. Beef Calves
    • 10.2.2. Dairy Calves
  • 10.3. Heifers

11. Bovine Respiratory Disease Treatment Market, by Distribution Channel

  • 11.1. Feed Mills
    • 11.1.1. Commercial Mills
    • 11.1.2. Onfarm Mills
  • 11.2. Online Pharmacies
    • 11.2.1. Animal Health Platforms
    • 11.2.2. General ERetail
  • 11.3. Veterinary Clinics
    • 11.3.1. Independent Clinics
    • 11.3.2. Large Practices

12. Bovine Respiratory Disease Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bovine Respiratory Disease Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bovine Respiratory Disease Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Bovine Respiratory Disease Treatment Market

16. China Bovine Respiratory Disease Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aratana Therapeutics, Inc.
  • 17.6. Ashish Life Science Pvt. Ltd.
  • 17.7. Bimeda Inc.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Ceva Sante Animale S.A.
  • 17.10. Dechra Pharmaceuticals PLC
  • 17.11. Elanco Animal Health Incorporated
  • 17.12. Huvepharma AD
  • 17.13. IDEXX Laboratories, Inc.
  • 17.14. India Immunologicals Ltd.
  • 17.15. Inovio Pharmaceuticals, Inc.
  • 17.16. Intas Pharmaceuticals Ltd.
  • 17.17. Kyoritsu Seiyaku Corporation
  • 17.18. Med-Pharmex Ltd.
  • 17.19. Merck & Co., Inc.
  • 17.20. Neogen Corporation
  • 17.21. Novartis Animal Health
  • 17.22. Ourofino Saude Animal S.A.
  • 17.23. Phibro Animal Health Corporation
  • 17.24. Plumbline Life Sciences
  • 17.25. Vetoquinol S.A.
  • 17.26. Virbac S.A.
  • 17.27. Zoetis Inc.
  • 17.28. Zydus Animal Health and Investments Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 284. AS